Abel Hall LLC Invests $202,000 in Guardant Health, Inc. $GH

Abel Hall LLC bought a new position in shares of Guardant Health, Inc. (NASDAQ:GH) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 3,882 shares of the company’s stock, valued at approximately $202,000.

Other hedge funds also recently made changes to their positions in the company. Signaturefd LLC increased its holdings in shares of Guardant Health by 50.5% during the second quarter. Signaturefd LLC now owns 635 shares of the company’s stock worth $33,000 after purchasing an additional 213 shares during the period. SVB Wealth LLC bought a new position in shares of Guardant Health during the first quarter worth approximately $54,000. BI Asset Management Fondsmaeglerselskab A S bought a new position in Guardant Health in the 1st quarter valued at about $97,000. CWM LLC increased its holdings in Guardant Health by 180.3% in the 1st quarter. CWM LLC now owns 2,296 shares of the company’s stock valued at $98,000 after buying an additional 1,477 shares during the period. Finally, Nkcfo LLC bought a new position in Guardant Health in the 1st quarter valued at about $107,000. 92.60% of the stock is owned by institutional investors.

Guardant Health Trading Up 3.0%

Shares of Guardant Health stock opened at $65.32 on Thursday. The firm has a market capitalization of $8.15 billion, a PE ratio of -19.50 and a beta of 1.53. The firm’s 50 day moving average is $58.48 and its 200 day moving average is $49.89. Guardant Health, Inc. has a 1 year low of $20.14 and a 1 year high of $68.00.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings results on Wednesday, July 30th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.08. The company had revenue of $232.09 million for the quarter, compared to the consensus estimate of $211.19 million. The company’s revenue for the quarter was up 31.0% compared to the same quarter last year. During the same period last year, the firm posted ($0.84) earnings per share. Guardant Health has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Insider Activity at Guardant Health

In related news, CEO Helmy Eltoukhy sold 300,000 shares of Guardant Health stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $59.45, for a total transaction of $17,835,000.00. Following the sale, the chief executive officer directly owned 2,123,499 shares of the company’s stock, valued at approximately $126,242,015.55. The trade was a 12.38% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Medina Manuel Hidalgo sold 2,165 shares of Guardant Health stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $54.16, for a total transaction of $117,256.40. Following the sale, the director owned 851 shares in the company, valued at approximately $46,090.16. This represents a 71.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 302,691 shares of company stock worth $17,981,965 over the last ninety days. 6.10% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several research firms have commented on GH. Guggenheim raised their target price on shares of Guardant Health from $56.00 to $67.00 and gave the company a “buy” rating in a report on Thursday, September 25th. Scotiabank raised their target price on shares of Guardant Health from $57.00 to $60.00 and gave the company a “sector outperform” rating in a report on Thursday, July 31st. Weiss Ratings reissued a “sell (d-)” rating on shares of Guardant Health in a report on Wednesday. Raymond James Financial raised their target price on shares of Guardant Health from $59.00 to $61.00 and gave the company an “outperform” rating in a report on Thursday, July 31st. Finally, TD Cowen raised their target price on shares of Guardant Health from $63.00 to $72.00 and gave the company a “buy” rating in a report on Thursday, September 25th. Twenty-three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $65.86.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.